News Breaks |
|
|
| March 29, 2012 |
| 13:55 EDT |  | BAX, BAX, BAYRY, BAYRY, BIIB, BIIB, PBTH, PBTH, NVO, NVO | Leerink's biotech analyst holds an analyst/industry conference call
Biotech Analyst Schimmer discusses the outlook for long-acting factor replacements in hemophilia on an Analyst/Industry conference call. Relevant covered companies BAX, BAYRY, BIIB, PBTH and NVO may be included on the Analyst/Industry conference call to be held on March 29 at 2 pm. |
|
|
News For BAX;BAYRY;BIIB;PBTH;NVO From The Last 14 Days Check below for free stories on BAX;BAYRY;BIIB;PBTH;NVO the last two weeks. |
|
|
| May 21, 2013 |
| 09:09 EDT |  | BAX | Baxter granted authorization by European Commission for use of HyQvia
Baxter International (BAX) and Halozyme Therapeutics (HALO) announced that the European Commission has granted Baxter marketing authorization in all European Union Member States for the use of HyQvia as replacement therapy for adult patients with primary and secondary immunodeficiencies. Baxter will introduce HyQvia in select countries during 2013 and plans to expand the launch to other EU countries in 2014. |
|
| 07:24 EDT | | BIIB | Global Health Care to host a conference
 Subscribe for More Information |
|
| 05:44 EDT | | BIIB | Biogen submits application to FDA for approval of Plegridy in RMS
Subscribe for More Information |
|
| May 20, 2013 |
| 17:20 EDT | | BAYRY | Regeneron,, Bayer, Genentech resolve certain patent disputes
Subscribe for More Information |
|
| 15:57 EDT |  | BIIB | Biogen IMS numbers should not be adjusted down at ISI Group
ISI Group confirmed with Biogen that Tecfidera is not captured by IMS and numbers should not be adjusted downward to reflect free drugs dispensed. |
|
| 07:39 EDT | | BIIB | Biogen weekly MS drug scripts up 26.5%, says Citigroup
Citigroup says weekly scripts for Biogen's multiple sclerosis drug Tecfidera were up 26.5% to 1,621. Citi says the launch of Tecfidera is on track to beat Q2 estimates by a wide margin and it keeps a Buy rating on shares of Biogen. |
|
| 07:28 EDT | | BAYRY | American Thoracic Society to hold a conference
Subscribe for More Information |
|
| May 17, 2013 |
| 06:33 EDT | | BAYRY | American Thoracic Society to hold a conference
Subscribe for More Information |
|
| May 16, 2013 |
| 07:29 EDT | | BIIB | Leerink to host a bus tour
Boston Biopharma Bus Tour travels throughout Boston on May 16-17. |
|
| May 15, 2013 |
| 11:43 EDT | | BAYRY | Bayer announces FDA approval for Xofigo as CRPC treatment
Subscribe for More Information |
| |
| May 14, 2013 |
| 15:09 EDT | | BIIB | Biogen has a conference call hosted by JPMorgan
JPMorgan Analysts Meacham and Kasimov host a conference call with CEO George Scangos and CFO Paul Clancy on May 17 at 10 am. |
|
| May 13, 2013 |
| 11:12 EDT | | BIIB | Biogen MS drug scripts grew 38% week-over-week, says Leerink
Subscribe for More Information |
|
| 09:44 EDT |  | BAX | Several companies reportedly interested in buying Adcock Ingram, Globes says
Subscribe for More Information |
|
| 07:34 EDT | | BIIB | Biogen says FDA accepts BLA for Eloctate
Subscribe for More Information |
|
| May 10, 2013 |
| 11:59 EDT |  | BAX | Options with decreasing implied volatility: GRPN DGIT BMC BAX TRIP
Subscribe for More Information |
|
| 08:00 EDT | | BIIB | Biogen should be bought on weakness before Q2 Tecfidera data, says Stifel
Stifel recommends buying Biogen on any weakness before the company reports Q2 Tecfidera sales data. The firm thinks that any continued strength in Tecfidera prescription data will cause analysts to revise their estimates higher, and it keeps a Buy rating on the shares. |
|
| May 9, 2013 |
| 16:59 EDT | | BIIB | Isis Pharmaceuticals earns $3.5M from Biogen
Subscribe for More Information |
|
| 05:54 EDT | | BAX | Stocks with implied volatility movement; DELL BAX
Subscribe for More Information |
|
| May 8, 2013 |
| 08:03 EDT | | BAX | Baxter valuation compelling, says Bernstein
Subscribe for More Information |
|
|
|
|
|
